Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies receives Saudi FDA approval for Plerixafor its first Maketing Authorization for the specialty oncology therapy globally'.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies has received Marketing Authorization from Saudi FDA for Plerixafor, a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma. This is the company's first Plerixafor approval anywhere in the world. The approval marks Venus Remedies' strategic entry into higher-value specialty injectables in regulated markets, moving away from commodity injectable volumes. Saudi Arabia is the largest pharmaceutical market in the GCC, projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033. The company will commercialize the 24mg/1.2ml injection through its existing international business network, targeting tertiary oncology centres and building hospital partnerships across the region.
This regulatory approval opens a new commercial front in a high-growth regulated market and marks Venus Remedies' deliberate pivot toward differentiated specialty therapies in oncology, which could improve revenue quality and margins over time.